Duke-NUS Medical School

PROSPECTIVE STUDENTS CURRENT STUDENTS RESEARCH MATTERS

NEWS

17 May 2018

Duke-NUS Medical School (Duke-NUS) and Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, have joined hands to study and develop a novel stem cell-based therapy to treat two chronic conditions: heart failure and vision loss.

Previous Pause Next

1 of 1

Events

23 July 2018

APEC RHSC CoE Pilot Workshop: Advanced Therapies 2018

30 July 2018

Medical Admissions Tests Q&A Webinar

13 August 2018

Mini Open House - Aug

EDUCATION TRACKS

MD Programme »

MD/PhD Programme »

PhD in Integrated Biology and Medicine (IBM) »

PhD in Biostatistics and Bioinformatics (IBB) »

VIDEO

Transforming Medicine, Improving Lives

USEFUL INFORMATON

ADMISSION REQUIREMENTS

Interested in a medical degree?

CONGRATULATIONS

SINGHEALTH DUKE-NUS RESEARCH APPRECIATION AWARDS

View the 2017 Winners!

SIGNATURE RESEARCH PROGRAMMES

Cancer & Stem Cell Biology»

Cardiovascular & Metabolic Disorders»

Emerging Infectious Diseases»

Health Services & Systems Research»

Neuroscience & Behavioural Disorders»

Read our
Student Blog

USEFUL INFORMATION

FEES & FINANCIAL AID

Tuition fees,
scholarships & bursaries

DUKE-NUS CENTRES

CORPORATE FACT SHEET

LIT REVIEWS - LEARNING IN 10

NEWS

17 May 2018

Duke-NUS Medical School (Duke-NUS) and Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, have joined hands to study and develop a novel stem cell-based therapy to treat two chronic conditions: heart failure and vision loss.

Previous Pause Next

1 of 1

Events

23 July 2018

APEC RHSC CoE Pilot Workshop: Advanced Therapies 2018

30 July 2018

Medical Admissions Tests Q&A Webinar

13 August 2018

Mini Open House - Aug

EDUCATION TRACKS

MD Programme »

MD/PhD Programme »

PhD Programme »

VIDEO

PhD Education

ACADEMIC CALENDAR

CURRICULUM AT A GLANCE

EDUCATIONAL RESEARCH

OUR MISSION

STUDENT LIFE

Student Interest Groups »

Community Service »

Student Wellness »

Read our
Student Blogs

THESIS MENTORS

USEFUL INFORMATION

FEES & FINANCIAL AID

Tuition fees,
scholarships & bursaries

Faculty Development

ACADEMIC MEDICINE PARTNERS PORTAL

EDUCATIONAL RESEARCH

NEWS

17 May 2018

Duke-NUS Medical School (Duke-NUS) and Novo Nordisk A/S (Novo Nordisk), a Danish multinational pharmaceutical company, have joined hands to study and develop a novel stem cell-based therapy to treat two chronic conditions: heart failure and vision loss.

Previous Pause Next

1 of 1

Events

23 July 2018

APEC RHSC CoE Pilot Workshop: Advanced Therapies 2018

30 July 2018

Medical Admissions Tests Q&A Webinar

13 August 2018

Mini Open House - Aug

SIGNATURE RESEARCH PROGRAMMES

Cancer & Stem Cell Biology »

Cardiovascular & Metabolic Disorders »

Emerging Infectious Diseases »

Health Services & Systems Research »

Neuroscience & Behavioural Disorders »

VIDEO

Centre for Computational Biology

MICROSCOPE - A RESEARCH BLOG

DISCOVERIES & DEVELOPMENTS

Research at Duke-NUS

DUKE-NUS CENTRES

Centre for Ageing Research and Education »

Centre for Cognitive Neuroscience »

Centre for Computational Biology »

Centre for Quantitative Medicine »

Centre of Regulatory Excellence »

Centre for Technology and Development »

Lien Centre for Palliative Care »

TRANSLATIONAL & CLINICAL RESEARCH

CLINICAL SCIENCES

ACADEMIC HOME FOR CLINICIANS

Enabling Research Careers

BUILDING CAPABILITIES & COLLABORATION

BRAIN MATTERS

ACADEMIC MEDICINE PARTNERS PORTAL

QUICK LINKS